This HTML5 document contains 140 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n9http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q40712404
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel artículo científico publicado en 1993 1993年论文 tieteellinen artikkeli articolo scientifico artikull shkencor vitskapeleg artikkel 1993年論文 1993年論文 1993 nî lūn-bûn научная статья article scientifique научни чланак artigo científico artigo científico bài báo khoa học 1993年论文 1993년 논문 1993年论文 tudományos cikk scienca artikolo מאמר מדעי مقالة علمية نشرت في أكتوبر 1993 vitenskapelig artikkel 1993年論文 scientific article published on October 1993 научна статия vetenskaplig artikel мақолаи илмӣ επιστημονικό άρθρο vedecký článok article scientific სამეცნიერო სტატია 1993年论文 1993年论文 articol științific artikulong pang-agham artículu científicu espublizáu en 1993 1993年論文 vědecký článek scientific article published on October 1993 bilimsel makale অক্টোবর ১৯৯৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 1993年論文 scientific article published on October 1993 article científic artikel ilmiah videnskabelig artikel artigo científico teaduslik artikkel wissenschaftlicher Artikel naučni članak artykuł naukowy наукова стаття, опублікована в жовтні 1993 1993年の論文 научни чланак บทความทางวิทยาศาสตร์ 1993年论文
p:P577
wds:Q40712404-D0266A21-2260-4078-B848-B08541FDF1BF
wdt:P577
1993-10-01T00:00:00Z
p:P2860
wds:Q40712404-03A13E42-09A8-48E6-A85B-2471A93E57EB wds:Q40712404-106789B5-420D-4B13-B125-B90D32B876F1 wds:Q40712404-1C708FB9-0FFE-4D09-B215-E814E234B7D6 wds:Q40712404-EF723107-06CC-4407-8669-B42A9122E57C wds:Q40712404-F3475134-1286-43D1-9BD8-D4DF99F0B935 wds:Q40712404-FE984EF2-04FA-4F6F-8739-16C9A1B792BE wds:Q40712404-9B0A5A5C-864D-41AA-BB0F-44195195A09E wds:Q40712404-A3727156-62F1-4D3D-B499-9098EE5933BD wds:Q40712404-A4C6E6B9-F647-4D7C-A902-7082A1DCEBAF wds:Q40712404-BAC3159E-13FE-4D16-A749-146ED5F41B8E wds:Q40712404-BDE09D39-A289-4236-BFD1-61CFE9C640A5 wds:Q40712404-C0576554-801D-4398-BB9F-36360F3DD122 wds:Q40712404-C3E60170-DC7D-441D-A4CF-FAD76D6AA785 wds:Q40712404-D3ED8620-2A0D-404C-8499-DD311E99C625 wds:Q40712404-EAEE54AD-6EE8-4FDF-84B9-702407FBC747 wds:Q40712404-2D25FDEA-9540-42F9-B9F6-4CB6047D9646 wds:Q40712404-4377B2DB-0220-4CF5-A77F-64328CE4EDB5 wds:Q40712404-4AFC91CC-A6D3-4714-9298-0E0564BD1F75 wds:Q40712404-4D3FE240-59D7-49FC-BC90-F7998B95E060 wds:Q40712404-5F9A1EFC-1582-473A-8436-A7DB25D9348F wds:Q40712404-67342CB7-97DE-4055-8613-A2677C693C39 wds:Q40712404-732D9945-553B-4094-863E-A9CEC245869F wds:Q40712404-74B9B5E1-5C84-4F15-B2D6-69DF0D42AA1E wds:Q40712404-79C7509D-3EFF-4859-BB55-C58B697AA432
wdt:P2860
wd:Q40746791 wd:Q34617823 wd:Q42212983 wd:Q44757950 wd:Q34249915 wd:Q69907015 wd:Q42006197 wd:Q44258107 wd:Q57584900 wd:Q69045162 wd:Q68207061 wd:Q69481813 wd:Q67733453 wd:Q70292216 wd:Q34251111 wd:Q68128079 wd:Q40732570 wd:Q40741748 wd:Q69812135 wd:Q34550152 wd:Q40759502 wd:Q44066321 wd:Q45197356 wd:Q41017837
p:P2093
wds:Q40712404-676BBE5B-AB38-4696-8B13-9F0EF54B081D wds:Q40712404-717F80BF-44E7-4EE8-99FA-80022FD2860D wds:Q40712404-9EF54A16-1690-444A-A7F4-5C7BBC56F27A wds:Q40712404-DB78F9FE-4D72-4039-91EF-1016B1A50D40 wds:Q40712404-DD6166DD-E1C4-4676-967D-4ED763ADD7D0
wdt:P2093
J A Hessels L F Verdonck G W van Imhoff J M Raemaekers W E Fibbe
rdfs:label
The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study
skos:prefLabel
The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study
schema:name
The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study
p:P1476
wds:Q40712404-39954E9D-81BF-4EA3-8F99-F058FEE23028
wdt:P1476
The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study
p:P304
wds:Q40712404-495FCA0C-4793-4438-9F76-F299FABA4AD8
wdt:P304
175-181
p:P31
wds:Q40712404-9CDCAEA9-FEC1-4332-954F-3D0B12A1FCD6
wdt:P31
wd:Q13442814
p:P698
wds:Q40712404-7C49074E-781A-4195-A5CD-36475AD7EA63
wdtn:P698
n11:8218538
wdt:P698
8218538
p:P1433
wds:Q40712404-EE4D4ECF-DD91-435E-9FCC-25C0E877AF24
wdt:P1433
wd:Q15766509
p:P433
wds:Q40712404-34295D0D-FE69-4809-9CA7-554285A0B832
p:P478
wds:Q40712404-419BC504-4270-4AA9-930F-3C5959A3CA64
wdt:P433
4
wdt:P478
67
p:P356
wds:Q40712404-C9831CA2-D472-4784-B657-D7D54ED7D6F2
wdtn:P356
n9:BF01695864
wdt:P356
10.1007/BF01695864